Flachenecker Peter, Kobelt Gisela, Berg Jenny, Capsa Daniela, Gannedahl Mia
Neurological Rehabilitation Center Quellenhof, Bad Wildbad, Germany.
European Health Economics, Mulhouse, France.
Mult Scler. 2017 Aug;23(2_suppl):78-90. doi: 10.1177/1352458517708141.
To estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated.
This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in EUR 2015.
A total of 5475 patients (mean age 52 years) participated in Germany. In all, 84% were below retirement age, and of these, 51% were employed. Employment was related to disease severity, and MS affected productivity at work for 80% of patients. Overall, 96% and 78% of patients experienced fatigue and cognitive difficulties as a problem, respectively. The mean utility and total annual costs were 0.786 and 28,200€ at Expanded Disability Status Scale (EDSS) 0-3, 0.586 and €44,000 at EDSS 4-6.5 and 0.273 and €62,700 at EDSS 7-9, respectively. The mean cost of a relapse was estimated at €2500.
This study provides current health economic data on MS in Germany that are important for the development of health policies and for estimating the value of the current and future treatments.
为了评估针对多发性硬化症（MS）的干预措施的价值（在无法观察到终身成本和结果的情况下），必须将结果数据与成本相结合。这就要求定期更新成本数据。
本研究是一项在16个国家开展的横断面回顾性研究的一部分，收集了MS患者的资源消耗、工作能力、健康相关生活质量（HRQoL）和常见症状的数据。从社会角度按严重程度水平以2015年欧元呈现描述性分析结果。
德国共有5475名患者（平均年龄52岁）参与。总体而言，84%的患者未达到退休年龄，其中51%受雇工作。就业情况与疾病严重程度相关，80%的患者的MS影响了工作效率。总体而言，分别有96%和78%的患者将疲劳和认知困难视为问题。在扩展残疾状态量表（EDSS）0 - 3级时，平均效用和每年总成本分别为0.786和28,200欧元；在EDSS 4 - 6.5级时，分别为0.586和44,000欧元；在EDSS 7 - 9级时，分别为0.273和62,700欧元。一次复发的平均成本估计为2500欧元。
本研究提供了德国MS的当前卫生经济数据，这些数据对于卫生政策的制定以及评估当前和未来治疗的价值具有重要意义。
